Navigation Links
GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
Date:6/18/2008

- Company To Actively Pursue Acquisition Opportunities -

BRIDGEWATER, N.J. and NEW YORK, June 18 /PRNewswire/ -- GANIC Pharmaceuticals, a new specialty pharmaceutical company, today announced its launch backed by Warburg Pincus, the leading global private equity firm. Warburg Pincus has made an initial investment in GANIC from Warburg Pincus Private Equity X, L.P., a $15 billion fund, which closed in April.

GANIC Pharmaceuticals was founded by a highly seasoned group of senior executives with 65 years of collective experience in the pharmaceutical industry, in partnership with Warburg Pincus. The company's founders include Paul Edick, Chief Executive Officer, Chief Financial Officer Corey Fishman, and Chief Commercial Officer Chris Maltese, all formerly senior executives at MedPointe Pharmaceuticals.

Paul Edick, CEO of GANIC Pharmaceuticals, said, "We see tremendous opportunities for profitable growth and expansion across our targeted areas of focus. We believe that we have the expertise, industry networks, talent base and funding to begin executing towards our objectives. We are very pleased to have as our sole investor, Warburg Pincus, a firm with great insight and expertise in our arena, which shares our strategic vision to build a great company."

GANIC Pharmaceuticals will focus on building a substantial enterprise by acquiring revenue-generating companies, portfolios and/or products and by investing in innovation and acquiring pipeline development assets. GANIC plans to target certain specialty pharmaceutical areas.

Commenting on the investment, Jonathan S. Leff, a Managing Director of Warburg Pincus, stated, "We are delighted to partner with the GANIC team, which has a proven track record for delivering value to investors and the pharmaceutical marketplace. We are confident that their strategy and ability to execute effectively, when combined with our funding and strategic support, will enable them to build a substantial and important pharmaceutical company." In conjunction with this investment, Mr. Leff, Managing Director Stewart Hen and Principal Cecilia Gonzalo of Warburg Pincus will join GANIC Pharmaceuticals' board of directors.

About GANIC Pharmaceuticals

Based in New Jersey, GANIC Pharmaceuticals is a new specialty pharmaceutical company, founded by a highly seasoned group of senior executives with 65 years of collective experience in the pharmaceutical industry, in partnership with Warburg Pincus, a leading global private equity firm. The company is focused on building a fully-integrated pharmaceuticals enterprise focused on certain specialty areas.

About Warburg Pincus

Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than $35 billion of assets under management. Warburg Pincus' investments are focused on a range of sectors in North America, Europe and Asia, including financial services, healthcare, industrial, technology, media and telecommunications, energy, consumer and retail and real estate. Since inception, the firm has raised 12 private equity funds that have invested more than $31 billion in approximately 600 companies in more than 30 countries. The firm has invested $6.6 billion in healthcare-related companies around the world, including approximately $1.6 billion to help build nearly 40 biotechnology and pharmaceutical companies. The firm has an active global portfolio of more than 125 companies and offices in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information, visit http://www.warburgpincus.com.

Business Inquiries

Corey Fishman

GANIC Pharmaceuticals

908-252-9404

cfishman@ganicpharma.com

Media Inquiries

Todd Fogarty or Joseph Kuo

Kekst and Company

212-521-4800

todd-fogarty@kekst.com or joe-kuo@kekst.com


'/>"/>
SOURCE GANIC Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials
2. SAFC Hitech Launches Metalorganic Bulk Vapor Distribution System for Compound Semiconductor Manufacturing
3. Directed self-ordering of organic molecules for electronic devices
4. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
5. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
8. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
9. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
10. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
11. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and ... Cell (hESC) Research - Global Strategic Business Report" report to ... ... (hESC) Research in US$ Million. Annual estimates and forecasts are provided ... derived from primary and secondary research. The report ...
(Date:3/24/2017)... Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company ... vaccines, today announced participation at the following conferences: ... and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at ... New York, NY . Agenus will participate in ... am: Robert B. Stein , M.D., Ph.D., President, ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
Breaking Biology News(10 mins):